"Gradon's leadership in working with our partners, including Biogen Idec, Bristol-Myers Squibb, Johnson & Johnson and Merck, has greatly contributed to our success in managing our current portfolio. To date, Sunesis has received approximately $57 million through payments resulting from collaborations," said Mr. Swisher. "Strategic collaborations that allow us to take full advantage of our proprietary drug discovery engine, Tethering(R), as well as the in-licensing of highly promising compounds that complement our existing internal portfolio of product candidates, are important aspects of our business plan."
As Senior Director, Business Development, Mr. Knotts has been responsible for the implementation of Sunesis' partnering strategy and has played a central role in the management of Sunesis' internal portfolio review and prioritization process. From 2002 to 2003, Mr. Knotts served as Senior Director, Business Development for Xenogen Corporation where he set strategy and took a lead role in several deals for Xenogen's biophotonic imaging product line. From 1995 to 2001, Mr. Knotts held positions of increasing responsibility, including Director, Strategic Marketing and Business Development for Roche Bioscience, playing a significant global role in strategic marketing and new product planning for all programs within the inflammatory diseases therapy area. From 1991 to 1994, Mr. Knotts conducted market, contract and financial analysis with Syntex Corporation. Mr. Knotts holds a B.S. in Finance from Brigham Young University and received an M.B.A. from the University of Notre Dame.